177 related articles for article (PubMed ID: 35906744)
1. Substrate Peptidomimetic Inhibitors of P. falciparum Plasmepsin X with Potent Antimalarial Activity.
Richardson LW; Ashton TD; Dans MG; Nguyen N; Favuzza P; Triglia T; Hodder AN; Ngo A; Jarman KE; Cowman AF; Sleebs BE
ChemMedChem; 2022 Sep; 17(18):e202200306. PubMed ID: 35906744
[TBL] [Abstract][Full Text] [Related]
2. Enhanced antimalarial activity of plasmepsin V inhibitors by modification of the P
Nguyen W; Hodder AN; de Lezongard RB; Czabotar PE; Jarman KE; O'Neill MT; Thompson JK; Jousset Sabroux H; Cowman AF; Boddey JA; Sleebs BE
Eur J Med Chem; 2018 Jun; 154():182-198. PubMed ID: 29800827
[TBL] [Abstract][Full Text] [Related]
3. Macrocyclic Peptidomimetic Plasmepsin X Inhibitors with Potent
Kovada V; Withers-Martinez C; Bobrovs R; Ce Rule HN; Liepins E; Grinberga S; Hackett F; Collins CR; Kreicberga A; Jiménez-Díaz MB; Angulo-Barturen I; Rasina D; Suna E; Jaudzems K; Blackman MJ; Jirgensons A
J Med Chem; 2023 Aug; 66(15):10658-10680. PubMed ID: 37505188
[TBL] [Abstract][Full Text] [Related]
4. Discovery and Characterization of Potent, Efficacious, Orally Available Antimalarial Plasmepsin X Inhibitors and Preclinical Safety Assessment of
Lowe MA; Cardenas A; Valentin JP; Zhu Z; Abendroth J; Castro JL; Class R; Delaunois A; Fleurance R; Gerets H; Gryshkova V; King L; Lorimer DD; MacCoss M; Rowley JH; Rosseels ML; Royer L; Taylor RD; Wong M; Zaccheo O; Chavan VP; Ghule GA; Tapkir BK; Burrows JN; Duffey M; Rottmann M; Wittlin S; Angulo-Barturen I; Jiménez-Díaz MB; Striepen J; Fairhurst KJ; Yeo T; Fidock DA; Cowman AF; Favuzza P; Crespo-Fernandez B; Gamo FJ; Goldberg DE; Soldati-Favre D; Laleu B; de Haro T
J Med Chem; 2022 Oct; 65(20):14121-14143. PubMed ID: 36216349
[TBL] [Abstract][Full Text] [Related]
5. Insight into selectivity of peptidomimetic inhibitors with modified statine core for plasmepsin II of Plasmodium falciparum over human cathepsin D.
Dali B; Keita M; Megnassan E; Frecer V; Miertus S
Chem Biol Drug Des; 2012 Apr; 79(4):411-30. PubMed ID: 22129033
[TBL] [Abstract][Full Text] [Related]
6. Basis for drug selectivity of plasmepsin IX and X inhibition in Plasmodium falciparum and vivax.
Hodder AN; Christensen J; Scally S; Triglia T; Ngo A; Birkinshaw RW; Bailey B; Favuzza P; Dietrich MH; Tham WH; Czabotar PE; Lowes K; Guo Z; Murgolo N; Lera Ruiz M; McCauley JA; Sleebs BE; Olsen D; Cowman AF
Structure; 2022 Jul; 30(7):947-961.e6. PubMed ID: 35460613
[TBL] [Abstract][Full Text] [Related]
7. Picomolar Inhibition of Plasmepsin V, an Essential Malaria Protease, Achieved Exploiting the Prime Region.
Gambini L; Rizzi L; Pedretti A; Taglialatela-Scafati O; Carucci M; Pancotti A; Galli C; Read M; Giurisato E; Romeo S; Russo I
PLoS One; 2015; 10(11):e0142509. PubMed ID: 26566224
[TBL] [Abstract][Full Text] [Related]
8. Plasmepsin Inhibitors in Antimalarial Drug Discovery: Medicinal Chemistry and Target Validation (2000 to Present).
Cheuka PM; Dziwornu G; Okombo J; Chibale K
J Med Chem; 2020 May; 63(9):4445-4467. PubMed ID: 31913032
[TBL] [Abstract][Full Text] [Related]
9. Azole-based non-peptidomimetic plasmepsin inhibitors.
Kinena L; Leitis G; Kanepe-Lapsa I; Bobrovs R; Jaudzems K; Ozola V; Suna E; Jirgensons A
Arch Pharm (Weinheim); 2018 Sep; 351(9):e1800151. PubMed ID: 30063266
[TBL] [Abstract][Full Text] [Related]
10. Antimalarial evaluation of copper(II) nanohybrid solids: inhibition of plasmepsin II, a hemoglobin-degrading malarial aspartic protease from Plasmodium falciparum.
Mohapatra SC; Tiwari HK; Singla M; Rathi B; Sharma A; Mahiya K; Kumar M; Sinha S; Chauhan SS
J Biol Inorg Chem; 2010 Mar; 15(3):373-85. PubMed ID: 19946719
[TBL] [Abstract][Full Text] [Related]
11. Plasmepsins IX and X are essential and druggable mediators of malaria parasite egress and invasion.
Nasamu AS; Glushakova S; Russo I; Vaupel B; Oksman A; Kim AS; Fremont DH; Tolia N; Beck JR; Meyers MJ; Niles JC; Zimmerberg J; Goldberg DE
Science; 2017 Oct; 358(6362):518-522. PubMed ID: 29074774
[TBL] [Abstract][Full Text] [Related]
12. Exploration of the P3 region of PEXEL peptidomimetics leads to a potent inhibitor of the Plasmodium protease, plasmepsin V.
Gazdik M; Jarman KE; O'Neill MT; Hodder AN; Lowes KN; Jousset Sabroux H; Cowman AF; Boddey JA; Sleebs BE
Bioorg Med Chem; 2016 May; 24(9):1993-2010. PubMed ID: 27021426
[TBL] [Abstract][Full Text] [Related]
13. Peptidomimetic plasmepsin inhibitors with potent anti-malarial activity and selectivity against cathepsin D.
Zogota R; Kinena L; Withers-Martinez C; Blackman MJ; Bobrovs R; Pantelejevs T; Kanepe-Lapsa I; Ozola V; Jaudzems K; Suna E; Jirgensons A
Eur J Med Chem; 2019 Feb; 163():344-352. PubMed ID: 30529637
[TBL] [Abstract][Full Text] [Related]
14. Deciphering the mechanism of potent peptidomimetic inhibitors targeting plasmepsins - biochemical and structural insights.
Mishra V; Rathore I; Arekar A; Sthanam LK; Xiao H; Kiso Y; Sen S; Patankar S; Gustchina A; Hidaka K; Wlodawer A; Yada RY; Bhaumik P
FEBS J; 2018 Aug; 285(16):3077-3096. PubMed ID: 29943906
[TBL] [Abstract][Full Text] [Related]
15. Identification of potent inhibitors of Plasmodium falciparum plasmepsin II from an encoded statine combinatorial library.
Carroll CD; Patel H; Johnson TO; Guo T; Orlowski M; He ZM; Cavallaro CL; Guo J; Oksman A; Gluzman IY; Connelly J; Chelsky D; Goldberg DE; Dolle RE
Bioorg Med Chem Lett; 1998 Sep; 8(17):2315-20. PubMed ID: 9873534
[TBL] [Abstract][Full Text] [Related]
16. Dual Plasmepsin-Targeting Antimalarial Agents Disrupt Multiple Stages of the Malaria Parasite Life Cycle.
Favuzza P; de Lera Ruiz M; Thompson JK; Triglia T; Ngo A; Steel RWJ; Vavrek M; Christensen J; Healer J; Boyce C; Guo Z; Hu M; Khan T; Murgolo N; Zhao L; Penington JS; Reaksudsan K; Jarman K; Dietrich MH; Richardson L; Guo KY; Lopaticki S; Tham WH; Rottmann M; Papenfuss T; Robbins JA; Boddey JA; Sleebs BE; Sabroux HJ; McCauley JA; Olsen DB; Cowman AF
Cell Host Microbe; 2020 Apr; 27(4):642-658.e12. PubMed ID: 32109369
[TBL] [Abstract][Full Text] [Related]
17. Role of Plasmodium falciparum digestive vacuole plasmepsins in the specificity and antimalarial mode of action of cysteine and aspartic protease inhibitors.
Moura PA; Dame JB; Fidock DA
Antimicrob Agents Chemother; 2009 Dec; 53(12):4968-78. PubMed ID: 19752273
[TBL] [Abstract][Full Text] [Related]
18. Structural basis for plasmepsin V inhibition that blocks export of malaria proteins to human erythrocytes.
Hodder AN; Sleebs BE; Czabotar PE; Gazdik M; Xu Y; O'Neill MT; Lopaticki S; Nebl T; Triglia T; Smith BJ; Lowes K; Boddey JA; Cowman AF
Nat Struct Mol Biol; 2015 Aug; 22(8):590-6. PubMed ID: 26214367
[TBL] [Abstract][Full Text] [Related]
19. In vitro and in silico studies of naphthoquinones and peptidomimetics toward Plasmodium falciparum plasmepsin V.
Sittikul P; Songtawee N; Kongkathip N; Boonyalai N
Biochimie; 2018 Sep; 152():159-173. PubMed ID: 30103899
[TBL] [Abstract][Full Text] [Related]
20.
Sharma PP; Kumar S; Kaushik K; Singh A; Singh IK; Grishina M; Pandey KC; Singh P; Potemkin V; Poonam ; Singh G; Rathi B
J Biomol Struct Dyn; 2022 Nov; 40(18):8352-8364. PubMed ID: 33870856
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
